ValueJune 8, 2026

Buy the Dip Monday: Insiders Deploy $16.8M Into 26% Drawdowns While ROIC Holds Above 19%

Top 5 Pixie Picks

This Week's Setup

Four energy and mining names sit 18 to 26 percent off their peaks while printing ROIC above 19% and free cash flow yields beyond 6%, a combination that historically marks structural undervaluation rather than broken business models.

Three pharma names hold gross margins above 72% and trade below 18× P/E while insiders added $16.8 million net across the past six months, with Regeneron alone accounting for $6.2 million of executive purchases at a 26% drawdown.

The S&P 500 CAPE Shiller ratio stands at 38.9, yet earnings yields on six of eight names exceed 5.7%, creating a yield spread that widens as rates remain elevated and the broad index trades at historically stretched multiples.

Quick Scan

#	Ticker	One-line thesis
1	REGN	85% margin pharma, $6.2M insider buys, 26% off peak
2	GDX	Gold miners 25% down, bear-market entry at 17× P/E
3	GSK	72% margin, 20% ROIC, 3.7% yield at 21% drawdown
4	EQT	60% revenue growth, 9% ROIC, 20% off peak
5	GILD	24% ROIC, 79% margin, $6.1M insider adds at 19% off
6	NEM	30% ROIC miner, 21% revenue growth, 19% drawdown
7	INCY	111% ROIC, 93% margin, 21% revenue growth, 17% off
8	MPLX	7.8% yield midstream, 19% ROIC, 8% off peak

The 8 Names

1. Regeneron Pharmaceuticals, Inc. (REGN)

P/E: 14.74 | Earnings yield: 6.78% | 52w drawdown: -26.44%

Regeneron sits 26% off its peak while posting an 85% gross margin and 17% ROIC, pricing in a deceleration that the 10-year normalized P/E of 15.7 suggests is already reflected in the multiple. The $833 average analyst target implies 38% upside from $604, a gap that widens when you anchor to the 6% FCF yield and 6.8% earnings yield against a normalized valuation barely above current levels.

Insiders added $6.2 million net over six months across 403,632 shares, with buy activity hitting 24.6% of transactions and sell activity under 0.3%. That ratio signals conviction rather than routine diversification, particularly when executives deploy capital into a name already trading at a 26% drawdown.

Revenue growth slowed to 1% year-over-year, flagging either product maturity or temporary channel dynamics. The market is pricing for the former; any acceleration in top-line momentum from pipeline readouts or label expansions will reset the valuation anchor quickly.

2. VanEck Gold Miners ETF (GDX)

P/E: 17.02 | Earnings yield: 5.87% | 52w drawdown: -25.09%

Gold miners entered a bear market with GDX down 25% while the underlying commodity fell just 3% on Friday's session, a disconnect that historically marks capitulation in levered mining equities rather than fundamental deterioration. The 17× P/E compresses the sector's earnings yield to 5.9%, a level that typically attracts capital rotation when broader equity multiples trade at 38.9× on the Shiller CAPE.

Leveraged miner ETFs like NUGT collapsed 17% in a single session on modest gold price moves, exposing the structural fragility of triple-levered products that decay through volatility rather than directional bets. GDX offers unlevered exposure, but the headline risk from derivative products spills into sentiment for the entire mining complex.

Barron's framed the miner selloff as a buying opportunity, citing valuation compression and the sector's historical mean reversion pattern after sharp drawdowns. The setup here depends on whether gold stabilizes above technical support levels that held through prior cycles, a variable not captured in the ETF's current earnings multiple.

3. GSK plc (GSK)

P/E: 12.79 | Earnings yield: 7.82% | 52w drawdown: -20.59%

GSK prints a 72% gross margin and 20% ROIC while trading at 12.8× P/E, a combination that typically signals either hidden structural risk or temporary sentiment dislocation. The 7.8% earnings yield sits 440 basis points above the normalized 10-year earnings yield of 3.4%, compressing valuation below the company's own historical range despite stable margin performance.

Insiders held steady over six months with $5 million in activity but zero net share change, a pattern that reflects maintenance-level transactions rather than directional conviction. The absence of selling pressure at a 21% drawdown is worth noting, but the lack of incremental buying limits the signal strength.

The $58 analyst target implies 18% upside, a modest premium that suggests the Street is pricing in patent cliff risk or pipeline uncertainty that hasn't yet materialized in margin or ROIC data. Hepatitis B trial data for bepirovirsen and oncology pipeline commentary from recent investor conferences will clarify whether the valuation discount is structural or transitory.

4. EQT Corporation (EQT)

P/E: 10.36 | Earnings yield: 9.65% | 52w drawdown: -19.99%

EQT grew revenue 60% year-over-year while printing 9% ROIC and an 8.3% FCF yield, positioning the company at the intersection of natural gas demand tied to data center infrastructure and consolidation momentum reshaping the energy sector. The 10.4× P/E compresses earnings yield to 9.7%, a spread that widens further when compared to the normalized 10-year P/E of 17.8, flagging either a one-time earnings spike or persistent undervaluation relative to the company's own cycle.

Insiders added $5.7 million net over six months through 583,874 shares, with buy transactions hitting 15.1% of total activity and sells at 2.1%. That 7:1 buy-to-sell ratio typically signals executive confidence in a cyclical recovery or strategic catalyst that hasn't yet repriced into the stock.

The company sits 20% off its peak while 24/7 Wall St. flagged EQT as vulnerable to acquisition in the ongoing energy consolidation wave. If the setup is acquisition speculation rather than standalone fundamentals, the upside caps at the takeout premium; if it's operational, the $70 analyst target and 28% implied upside become the base case.

5. Gilead Sciences, Inc. (GILD)

P/E: 17.38 | Earnings yield: 5.75% | 52w drawdown: -18.80%

Gilead posts a 79% gross margin and 24% ROIC while sitting 19% off its peak, printing the highest ROIC in this week's screen alongside a 6% FCF yield that covers the 2.6% dividend yield with room for buybacks. The normalized 10-year P/E of 33.5 sits nearly double the current 17.4× multiple, a gap that reflects either structural margin compression baked into the forecast or temporary sentiment dislocation around HIV franchise maturity.

Insiders added $6.1 million net over six months, with Andrew Dickinson, Johanna Mercier, and CEO Daniel O'Day filing buys in May and early June at prices near current levels. The 53% buy transaction rate against 30% sell activity flags conviction rather than routine equity compensation adjustments.

⬡ Gilead and Lakefront Biotherapeutics acquired Ouro Medicines to advance an autoimmune pipeline that extends beyond the HIV and oncology franchises, signaling strategic diversification into inflammatory disease targets. The deal terms weren't disclosed, but the acquisition pattern here mirrors Gilead's historical playbook of in-licensing early-stage assets to derisk development timelines and broaden revenue exposure.

Only Pro and Free Trial readers get meta-analysis of the top 5 ranked Value stocks.

6. Newmont Corporation (NEM)

P/E: 14.23 | Earnings yield: 7.03% | 52w drawdown: -18.66%

Newmont prints 30% ROIC and 21% revenue growth year-over-year while trading at 14.2× P/E, a valuation that compresses the earnings yield to 7% and widens the gap between current multiples and the normalized 10-year P/E of 25.7. The company generated 6.2% FCF yield alongside a 53% gross margin, positioning the miner at the top end of operational efficiency within the gold complex.

Insiders Deborah Leyva, Maura Clark, and Harry Conger added modest share positions in mid-May, with total net buying at 16,605 shares over six months. The buy-to-sell ratio sits at 1.3:1, a muted signal compared to the 24.6% buy rate at Regeneron, but the timing at an 19% drawdown adds context when paired with the sector-wide miner selloff.

Jefferies raised the price target to $158 from $154 while maintaining a Buy rating, a $16 increment that signals incremental optimism but stops short of a fundamental rerating. The $143 consensus target implies 30% upside from $110, a spread that depends on gold's ability to hold above technical support and the miner complex avoiding further multiple compression from macro uncertainty.

7. Incyte Corporation (INCY)

P/E: 13.21 | Earnings yield: 7.57% | 52w drawdown: -16.72%

Incyte posts 111% ROIC and a 93% gross margin while growing revenue 21% year-over-year, the highest margin and ROIC combination in this week's screen. The 7.1% FCF yield compresses valuation to 13.2× P/E, a multiple that sits well below the normalized 10-year P/E of 34.9 and flags either structural earnings compression ahead or a temporary sentiment discount on a fundamentally sound business.

⬡ Incyte agreed to acquire Vega Therapeutics for up to $2 billion, adding autoimmune and inflammatory disease assets to a pipeline already weighted toward oncology and hematology. The deal expands Incyte's addressable market and derisks revenue concentration, but the $2 billion price tag and integration risk explain why the stock trades 17% below its peak despite operational strength.

Insiders Thomas Tray, Paul Clancy, and Jean-Jacques Bienaime added shares in late May, with $5.4 million in net buying over six months. The 12.5% buy rate against 5.4% sell activity flags modest conviction, tempered by the fact that the Vega acquisition will dilute near-term EPS and shift the valuation anchor toward pipeline execution rather than current cash generation.

8. MPLX LP (MPLX)

P/E: 11.97 | Earnings yield: 8.35% | 52w drawdown: -7.77%

MPLX prints a 7.8% distribution yield alongside 19% ROIC and an 8.4% earnings yield, positioning the midstream partnership as the highest-yielding name in this week's screen while sitting just 8% off its peak. The 7.3% FCF yield covers the distribution with room for deleveraging, and the normalized 10-year P/E of 13.4 sits close to the current 12× multiple, signaling stable valuation rather than cyclical compression.

Insiders Garry Peiffer, Ray Walker, and Frank Semple filed transactions in mid-May, but net share change over six months remains zero, reflecting maintenance activity rather than incremental buying. The absence of selling pressure at an 8% drawdown is neutral; the lack of executive adds limits the signal strength compared to the 15% buy rate at EQT or the $6.2 million net buying at Regeneron.

The 8% drawdown puts MPLX in the "Moderate dip" zone rather than the "Strong entry" category that defines the rest of this week's screen. The setup here is yield and cash flow stability rather than mean reversion from a deep selloff, a distinction that matters when the broader energy complex faces consolidation risk and cyclical uncertainty.

What to Watch

• July 21, EQT earnings: Estimates call for $0.56 EPS on $1.9 billion revenue; any upside surprise on data center-related gas demand will reset the growth narrative and test whether the 60% revenue growth rate is sustainable or a one-quarter spike.

• July 28, GILD and INCY earnings: Gilead's $7.4 billion revenue estimate and Incyte's $1.4 billion print will clarify whether the Ouro Medicines and Vega Therapeutics acquisitions are dilutive in the near term or accretive through pipeline optionality.

• July 30, REGN earnings: Estimates call for $10.85 EPS on $3.8 billion revenue; the CytomX partnership expansion and Lynozyfic trial results will test whether the 1% revenue growth rate accelerates or whether the $6.2 million in insider buying reflects executives anchoring to valuation rather than growth visibility.

• Mid-June FOMC decision: Any hawkish hold or dovish pivot will shift the yield spread calculation for the entire screen, widening or narrowing the gap between the 5.9% to 9.7% earnings yields here and the risk-free rate embedded in Treasury pricing.

Go Deeper

The value screener surfaces companies trading below normalized P/E multiples with strong cash flow and insider conviction.

Check out the full screener →

Pro-only analytics

Named tickers from this article open in the app with Pro or an active trial.

Stock Pixie Pro

See the full Buy the Dip screen — every pick, every metric, every day.

The app shows up to 10 rows on Free; the top 5 by Pixie rank keep ticker, name, and recent close private. Posts may name the top 5 for context. Pro and trial show every row on the screener, full identifiers, and the rest of Pro.

Start your free trial →

About the Stock Pixie Score

The Stock Pixie Score is a 0–10 composite that measures how well a stock matches the criteria for that screen. Scores reflect the strength of quantitative signals across valuation, quality, and trend factors weighted for the specific screener. A higher score means stronger alignment; above 8 indicates the algorithm finds the setup compelling across most of the metrics it tracks. It is a filter, not a forecast.

The Fine Print

Stock Pixie is not a registered investment adviser and does not offer financial advice. It is a stock screening platform that scores and ranks stocks using quantitative signals. You are responsible for your own research and investment decisions. Past performance does not guarantee future results.